Alexion Pharmaceuticals (ALXN) is an innovative, commercial-stage pharmaceutical company specializing in therapies for rare, hard-to-treat diseases. It has a market cap of about $29 billion. The stock has not moved much, expecting volatility, since early 2014, but revenue and earnings have risen substantially. Alexion has a strong pipeline. Given its current valuation, I believe that makes it a good investment for anyone with a long-term strategy.
ALXN reached a high price of $208.83 back in July 2015. During this last year, the 52-week low is $92.56, and the high $141.86. It closed on